Physician profile
Sam Som
NPI 1316084312
$2,368.82
in general payments reported to CMS, 2019-2025
20 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $682 · 2023: $541 · 2024: $663 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $421.64 | 2022-2024 | Wakix |
| Merck Sharp & Dohme LLC | $405.02 | 2022-2024 | Verquvo, Winrevair, Belsomra |
| Glaxosmithkline, LLC. | $369.22 | 2021-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $172.64 | 2021-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $124.81 | 2022-2025 | |
| Grifols USA, LLC | $120.46 | 2021-2024 | Prolastin-C Liquid |
| Genzyme Corporation | $108.05 | 2022-2024 | |
| Insmed, INC. | $89.87 | 2021 | |
| Sanofi-Aventis U.S. LLC | $89.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.90 | 2021-2023 | Jardiance |
| Mylan Specialty L.P. | $68.60 | 2023-2024 | Yupelri |
| Lilly USA, LLC | $63.29 | 2025 | Mounjaro, Zepbound |
| Avadel Cns Pharmaceuticals, LLC | $51.77 | 2024 | Lumryz |
| Bayer Healthcare Pharmaceuticals INC. | $45.62 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $32.43 | 2024 | Opsumit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $29.00 | 2022 | |
| Verona Pharma, INC. | $25.69 | 2025 | Ohtuvayre |
| Shield Therapeutics INC | $22.49 | 2025 | |
| Viatris Specialty LLC | $21.39 | 2025 | Yupelri |
| Electromed, INC. | $18.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Som listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.